Filtered By:
Condition: Thrombosis
Procedure: Coronary Angioplasty
This page shows you your search results in order of relevance. This is page number 14.
Order by Relevance | Date
Total 869 results found since Jan 2013.
Long-term Outcomes of Clopidogrel Monotherapy versus Prolonged Dual Antiplatelet Therapy beyond 12 Months after Percutaneous Coronary Intervention in High-risk Patients
CONCLUSION: Compared with prolonged DAPT, clopidogrel monotherapy showed similar long-term outcomes in patients at high-risk after second-generation DES implantation.PMID:33904262 | DOI:10.3346/jkms.2021.36.e106
Source: J Korean Med Sci - April 27, 2021 Category: General Medicine Authors: Dong Yeon Kim Sung Woo Cho Kyu Tae Park Jong Hwa Ahn Taek Kyu Park Yong Ho Jang Ki Hong Choi Joo Myung Lee Jeong Hoon Yang Young Bin Song Jin Ho Choi Seung Hyuk Choi Hyeon Cheol Gwon Sang Hoon Lee Joo Yong Hahn Source Type: research
Bivalirudin versus unfractionated heparin during percutaneous coronary intervention in high-bleeding-risk patients with acute coronary syndrome in contemporary practice
CONCLUSIONS: The treatment of bivalirudin showed better efficacy and safety as compared to UFH among patients with ACS undergoing PCI at high risk of bleeding in contemporary practice.PMID:34321166 | DOI:10.1016/j.biopha.2020.110758
Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie - July 29, 2021 Category: Drugs & Pharmacology Authors: Yahao Zhang Yanghui Zhang Zhiyu Liu Bin Zhang Guizhi Liu Kui Chen Source Type: research
Aspirin in the Modern Era of Cardiovascular Disease Prevention
Methodist Debakey Cardiovasc J. 2021 Sep 24;17(4):36-47. doi: 10.14797/mdcvj.293. eCollection 2021.ABSTRACTAspirin's antithrombotic effects have a long-established place in the prevention of cardiovascular disease (CVD), and its traditional use as a core therapy for secondary prevention of CVD is well recognized. However, with the advent of newer antiplatelet agents and an increasing understanding of aspirin's bleeding risks, its role across the full spectrum of modern CVD prevention has become less certain. As a consequence, recent trials have begun investigating aspirin-free strategies in secondary prevention. For exampl...
Source: Methodist DeBakey Cardiovascular Journal - November 26, 2021 Category: Cardiology Authors: Ella Murphy James M G Curneen John W McEvoy Source Type: research
